Skip to main content

Table 1 Baseline characteristics of patients receiving ICM

From: Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer

Variable

Number of patients

Number of patients, n (%)

16 (100)

Age, years, median (IQR)

64 (57.8; 69.3)

Gender, male, n (%)

7 (43.8)

Primary tumour, n (%)

 

 Lung cancer

11 (68.8)

 Malignant melanoma

4 (25)

 Pleural mesothelioma

1 (6.3)

UICC stages, n (%)

 

 IIIA

4 (25.0)

 IV

12 (75.0)

  1. %, as percent from total patient number n = 16; UICC, Union for International Cancer Care; VA, Viscum album L.; IQR, interquartile range
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us